mRNA Platform - Global Strategic Business Report

What`s New for 2023?

Special coverage on Russia-Ukraine war; global inflation; easing of 'zero-Covid' policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global mRNA Platform Market to Reach $120.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for mRNA Platform estimated at US$136.2 billion in the year 2022, is projected to decline to US$120.1 Billion by 2030, exhibiting a compounded average rate of decline of -1.6% over the analysis period 2022-2030. Covid-19 Vaccine, one of the segments analyzed in the report, will witness the steepest decline of -4.2% to reach US$96.5 Billion by the end of the analysis period. The decline is led by the waning pandemic, lower disease severity and reduced reliance on vaccines. The Cancer Vaccine segment, on the other hand, will continue to witness robust growth and reach US$18.3 billion over the next 8-year period.

The U.S. Market is Estimated at $61.6 Billion, While China is Forecast to Grow at 0.9% CAGR

The mRNA Platform market in the U.S. is estimated at US$61.6 Billion in the year 2022 and will continue to decline at a rate of -1.8% over the analysis period. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2030 trailing a CAGR of 0.9% over the analysis period 2022 to 2030. Rest of Asia-Pacific (excluding China) will remain the only other regional market to witness a positive growth of 0.5% over the analysis period to reach a projected market value of US$8.9 billion by 2030. Canada and Japan will each decline at -3.3% and -2.8% respectively over the 2022-2030 period.

Select Competitors (Total 96 Featured)-

AstraZeneca PLC
Asuragen, Inc.
Catalent Pharma Solutions
Altogen Labs
Arcturus Therapeutics, Inc.
BioNTech AG
CRISPR Therapeutics
Aldevron
AKESOgen, Inc.
baseclick GmbH
chimeron bio
Acuitas Therapeutics
Accent Therapeutics
Accanis Biotech F&E GmbH & Co KG
Avectas

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Impact of Covid-19 and a Looming Global Recession
The Race Between the Virus & Vaccines Intensifies
Effectiveness of Vaccinations
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Saving Lives with Vaccines
Dosing Interval Adjustment to Expand Coverage
Global COVID-19 Vaccine Inequity
Accessibility of Vaccines
Impact of Vaccine Inequity on the Economy
Impact of Vaccine Inequity on the Labor Market
Financing Vaccines
mRNA Platform - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
MRNA - A CONCEPTUAL UNDERSTANDING
MRNA: A New Approach to Medicine
Long Wait & Scientific Breakthroughs
mRNA Vaccines - An Introduction
With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
mRNA: Making Cells Act as Vaccine Factory
mRNA Vaccines: Advantages
mRNA Vaccines: Cons
mRNA Vaccine Approvals
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Traditional Vs. mRNA Vaccines: Key Differences
Traditional Vs. mRNA Vaccines: The Development Process
How mRNA Vaccine Works & Earlier Testing Efforts
mRNA Vaccines: Safety Quotient
Other Notable Efforts Centered on mRNA Technology
Overcoming Challenges
As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
GLOBAL MARKET OVERVIEW
Global mRNA Vaccines Market on a Dynamic Growth Track
Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead
COVID-19 mRNA Vaccine Approval Details
COVID-19 Funding Details of Moderna and Pfizer Vaccine
Production Capacity of mRNA Frontrunners in Millions of Doses for 2021
COVID-19 Pandemic: An Eventful Year for RNA
COVID-19 Cases Worldwide by Country: As on May 17, 2021
COVID-19’s Impact on Vaccine Development - A Transformative Shift to mRNA vaccines
mRNA Based Vaccines in Clinical Development
mRNA Vaccines in Phase IV Clinical Trials
mRNA Vaccines in Phase III Clinical Trials
mRNA Vaccines in Phase II Clinical Trials
Vaccines in Pipeline by Technology
Vaccine Technologies in Pre-Clinical Studies
VARIOUS VIRUS VARIANTS
COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge
Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
Investigating the Virulence Profile of India’s N440K Variant
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
Rising Cases in South Africa & Other Countries
California Strain Emerges to be More Contagious and Deadly
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study
mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
Pfizer and BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
After UK, US Gives Nod to Pfizer’s Vaccine
EU Approves Pfizer’s Vaccine
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna’s mRNA Vaccine Bags Approval from US FDA
Moderna Kick-Starts Inoculation in the US
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Recent Market Activity
COMPETITIVE SCENARIO
BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
List of BioNTech’s mRNA Candidates in Clinical Trials for Cancer
Moderna’s Ambitious Stride into Vaccine Development: From a Novice to Know All
Moderna’s mRNA Prophylactic Vaccines
mRNA Cancer Vaccines
mRNA Intratumoral Immuno-Oncology
mRNA Systemic Secreted & Cell Surface Therapeutics
mRNA Systemic Intracellular Therapeutics
Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
Noteworthy Startups Exploiting mRNA Technology
Providence Therapeutics
pHion Therapeutics
eTheRNA immunotherapies & 20Med Therapeutics
The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of Coronavirus Cases Drive the Market Demand
Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018
Number of AIDS-Related Deaths (in Thousands) by Region for 2018
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Increasing Healthcare Expenditure to Foster Market Growth
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Regulatory Landscape for mRNA Vaccines
Regulatory Pathway Dealing with mRNA Vaccines
mRNA Vaccine Patent Scenario
The Best Route of Administration for mRNA Vaccines
CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021)
mRNA CANCER VACCINES
Introduction
Cancer Vaccines Vs. Immunotherapies
Clinical Trials of mRNA Encoding Immunostimulants
mRNA Vaccines Vs. DNA Vaccines
Clinical Trials of mRNA Encoding TAAs
mRNA Vaccines Vs. Other Vaccines
Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
mRNA Benefits Profile
mRNA Vaccines for Covid-19 Pave the Way
Challenges
Personalized mRNA Vaccine
Clinical Overview of mRNA Cancer Vaccines
mRNA encoding Immunostimulants
mRNA vaccine encoding tumor-associated antigens
mRNA vaccine encoding Neoantigen, personalized vaccine
mRNA Influenza Vaccines
Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
Vaccines Built on mRNA
Clinical Trials for mRNA Vaccines
mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
mRNA: A Next-Generation Vaccination Approach
Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
mRNA Vaccines Vs. Other Flu Shots
mRNA Technology, H/N Spike Proteins & Clinical Trials
mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
Benefits & Limitations of mRNA Vaccines over Traditional Options

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: World mRNA Platform Market Analysis of Annual Sales in US$ Million for Years 2021 through 2027
TABLE 2: World Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
TABLE 3: World 5-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
TABLE 5: World 5-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027
TABLE 6: World Recent Past, Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
TABLE 7: World 5-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027
TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
TABLE 9: World 5-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027

III. MARKET ANALYSIS

UNITED STATES

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
US FDA Gives Nod to Pfizer and Moderna’s mRNA Vaccines
Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply

TABLE 10: USA Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 11: USA 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
CANADA

Vaccination Gathers Steam Across Canada
Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
COVID-19 Vaccine Deals in Canada
Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
Canada Grants Approval to Pfizer’s COVID-19 Shot for Use in Children in 12-15 Years Age Group

TABLE 12: Canada Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 13: Canada 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
JAPAN

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
COVID-19 Vaccination Programs in Japan Move Forward at Snail’s Pace
Reasons Responsible for Setback
Vaccine Timeline & Availability
Japan Demands for Vaccine-Related Data
People’s Low Trust in Vaccines
Japan’s Efforts to Develop Indigenous Vaccines
Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
Japan Pushes Shipments of Pfizer’s COVID-19 Shots to Vaccinate Elderly

TABLE 14: Japan Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 15: Japan 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
CHINA

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
BioNTech’s Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China

TABLE 16: China Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 17: China 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
EUROPE

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
EU Approves Pfizer’s Vaccine
EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU

TABLE 18: Europe Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
TABLE 19: Europe 5-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2027
TABLE 20: Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 21: Europe 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
FRANCE

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)

TABLE 22: France Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 23: France 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
GERMANY

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)

TABLE 24: Germany Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 25: Germany 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
ITALY

Italy Plans to Produce mRNA Vaccines Domestically

TABLE 26: Italy Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 27: Italy 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
UNITED KINGDOM

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Market Analysis
UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
UK’s Independent Vaccine Deals

TABLE 28: UK Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 29: UK 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
REST OF EUROPE
TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 31: Rest of Europe 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
ASIA-PACIFIC

mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
INDIA
Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
AUSTRALIA
Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
NEW ZEALAND
New Zealand Acquires Ultra-Cold Freezers to Store Pfizer’s COVID-19 Vaccine

TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 33: Asia-Pacific 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
REST OF WORLD

THE MIDDLE EAST
BAHRAIN
Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer’s Vaccine
AFRICA
SOUTH AFRICA
New Virus Variant in South Africa Creates a Challenge
Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
LATIN AMERICA
Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
BRAZIL
Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
MEXICO
Mexico’s Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine

TABLE 34: Rest of World Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
TABLE 35: Rest of World 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027

IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

AstraZeneca PLC
Asuragen, Inc.
Catalent Pharma Solutions
Altogen Labs
Arcturus Therapeutics, Inc.
BioNTech AG
CRISPR Therapeutics
Aldevron
AKESOgen, Inc.
baseclick GmbH
chimeron bio
Acuitas Therapeutics
Accent Therapeutics
Accanis Biotech F&E GmbH & Co KG
Avectas

What`s New for 2023?

Looking Ahead to 2023

Global mRNA Platform Market to Reach $120.1 Billion by 2030

The U.S. Market is Estimated at $61.6 Billion, While China is Forecast to Grow at 0.9% CAGR

Select Competitors (Total 96 Featured)-

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2027

MRNA Vaccines and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

mRNA Vaccines and Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography: Global Trends and Industry Analysis, 2022-2035